Medical Device

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market.

The common shares of Leveljump will commence trading at the open on May 12th under the symbol "JMPHF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQB Venture Market provides value and convenience to U.S. investors, brokers and institutions seeking to trade JMPHF. The OTCQB Venture Market is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. Trading on the OTCQB Market is intended to offer companies efficient, cost-effective access to the U.S. capital markets. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S.

Information relating to the Company, including copies of the Company's financial statements, are available on SEDAR at www.sedar.com.

"We are extremely proud to announce the commencement of trading on the OTCQB Venture Market," said Mitch Geisler, CEO and Chairman of Leveljump. "We are excited to share our vision for Leveljump with a wider pool of retail and institutional shareholders throughout the United States."

"We are pleased to welcome LevelJump Healthcare Corp. to the OTCQB Venture Market," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. "Trading on the TSX Venture Exchange in Canada and on the OTCQB Market in the U.S. will enable Leveljump to more efficiently build global investor awareness. We look forward to supporting the company and its shareholders."

Leveljump is also pleased to advise that B. Riley FBR, Inc. acted as its OTCQB sponsor. B. Riley FBR, is a full-service investment bank and subsidiary of B. Riley Financial, Inc. B. Riley FBR, based in Los Angeles with offices across the United States, provides corporate finance, research, sales and trading services.

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83643

News Provided by Newsfile via QuoteMedia

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti-cancer treatments.

The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. The research team at Harvard Medical School is led by Joan S. Brugge, PhD, who is the Louise Foote Pfeiffer Professor of Cell Biology and Co-Director of the Ludwig Cancer Center.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

 BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nanalysis Announces Results of AGM and Appointment of New Director

Nanalysis Scientific Corp. ("the Company", ("the Company", TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ) a leader in portable NMR machines and MRI technology for healthcare and industrial applications, is pleased to report that all proposed resolutions were approved at the Company's Annual General and Special Meeting of shareholders held on June 22, 2022 (the "Meeting"). The number of directors was set at 7 and all director nominees, as listed in the Management Information Circular dated May 20, 2022 (the "Information Circular"), were elected as directors of the Company at the Meeting to serve for a one-year term and hold office until the next annual meeting of shareholders. According to the proxy votes received from shareholders, the results were as follows:

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)

Nominees:


% For


% Withheld






Sean Krakiwsky


96.566 %


3.434 %

Martin Burian


95.592 %


4.408 %

Werner Gartner


99.852 %


0.148 %

Michal Okoniewski


99.852 %


0.148 %

Guido Cloetens


95.628 %


4.372 %

Rene Lenggenhager


99.852 %


0.148 %

Kham Lin


99.609 %


0.391 %

Shareholders voted 99.85% in favor of setting the number of directors at seven, 99.6% in favor of appointing Ernst & Young LLP, as auditor of the Company for the ensuing year and to authorize the Directors of the Company to fix the auditor's remuneration and 98.1% in favor for the approval of an amended stock option plan of the Company.

Corporate Update

The Company is pleased to welcome Kham Lin to Nanalysis's Board of Directors with immediate effect following shareholder approval at the Meeting.

Mr. Lin is currently a Managing Director at Nanalysis and was formerly the President and Chief Executive Officer of KPrime Technologies before the Company's acquisition by Nanalysis.  Over twenty plus years, Mr. Lin built KPrime, into a manufacturing representative business for global companies like Agilent Technologies, Metrohm USA , Sartorius LPS Division, and Leidos.  KPrime has a portfolio of sales and services in scientific detection and measuring equipment, financing, and asset management for chemical and security industries.  Mr. Lin resides and works in Calgary, Alberta, Canada but also splits time in Phoenix, Arizona at KPrime Headquarters.

About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nanalysis-announces-results-of-agm-and-appointment-of-new-director-301574013.html

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/23/c9517.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Continues Cannabis Market Expansion

Applied UV Continues Cannabis Market Expansion

Tru Infusion Places Significant Order

Largest Indoor Cannabis Cultivator in Arizona

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

~All nominated directors and proposed resolutions approved by shareholders~

 Greenlane Renewables Inc. ("Greenlane") (TSX: GRN) (FSE: 52G) is pleased to announce the results from its 2022 Annual General Meeting of Shareholders held on June 22, 2022 (the "Meeting"). Shareholders approved all matters submitted to them for approval at the annual general meeting. The results of the voting are set forth below:

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Receives Substantial Order from European Distributor

Applied UV Receives Substantial Order from European Distributor

Cellarius is One of Europe's Fastest Growing Companies

Expanding Airocide's Global Winery Market share

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×